Robotic Staging of Cervical Cancer With Simultaneous Detection of Primary Pelvic and Secondary Para-Aortic Sentinel Lymph Nodes: Reproducibility in a First Case Series

Autor: Philippe Van Trappen, Eveline De Cuypere, Nele Claes, Sarah Roels

Publikováno v: Frontiers in Surgery, Vol 9 (2022)

ObjectiveDiscrepancies exist among international guidelines on the surgical staging of para-aortic lymph nodes in locally advanced cervical cancer (LACC), varying from considering a para-aortic lymph node dissection, at least up to the inferior mesen

Externí odkaz: https://doaj.org/article/5e9cf2892b8f416dbc47a1382ddc6964

Robotic surgery in early and advanced ovarian cancer: Case selection for surgical staging and interval debulking surgery

Autor: Philippe Van Trappen, Eveline de Cuypere, Nele Claes

Publikováno v: European Journal of Obstetrics & Gynecology and Reproductive Biology. 280:7-11

During the last decade several case series have been published on robotic surgery in early and advanced stage ovarian cancer. Although most studies lack a significant oncological follow-up, more importantly criteria for patient selection for both rob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff396e8a533de3492f1756bc98da5009
https://doi.org/10.1016/j.ejogrb.2022.11.005

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6):a multicentre, open-label, single-arm, phase 2 study

Autor: Ugo De Giorgi, Bohuslav Melichar, Bente Lund, Signe Diness Vindeløv, Antonio González-Martín, Jeffrey R. Harris, Francesco Raspagliesi, Michael Gold, Claudio Zamagni, Andrés Redondo, Nicole Concin, Brigitte Honhon, Maria Bjurberg, Sandro Pignata, Melinda S L Teng, Matthew Schlumbrecht, Meaghan Tenney, Mansoor Raza Mirza, Reshma A. Rangwala, Charles Leath, Robert L. Coleman, Domenica Lorusso, Annouschka Laenen, Eveline De Cuypere, Lydia Gaba Garcia, Giovanni Scambia, Sven Mahner, William H. Bradley, Carolyn Muller, Nicola Spirtos, Margaret Smith, David Cibula, Leslie M Randall, Bradley J. Monk, Philipp Harter, Stephanie Henry, Sumeet Bhatia, Joshua Cohen, Menghui Chen, Christine Gennigens, Ignace Vergote, Luis Manso, Zdenek Kral, Amanda Jackson, Robin Farias-Eisner, Jean-Francois Baurain, Christof Vulsteke, David M. O'Malley, Frederic Forget, Linn Woelber, Mary Gordinier, Hannelore Denys, Leonardo Viana Nicacio

Publikováno v: Coleman, R L, Lorusso, D, Gennigens, C, González-Martín, A, Randall, L, Cibula, D, Lund, B, Woelber, L, Pignata, S, Forget, F, Redondo, A, Vindeløv, S D, Chen, M, Harris, J R, Smith, M, Nicacio, L V, Teng, M S L, Laenen, A, Rangwala, R, Manso, L, Mirza, M, Monk, B J, Vergote, I & The innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators 2021, ' Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study ', The Lancet Oncology, vol. 22, no. 5, pp. 609-619 . https://doi.org/10.1016/S1470-2045(21)00056-5

Summary Background Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody–drug conjugate,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::602debc1a5b7e94c93fe44ed1aa57b6a
https://vbn.aau.dk/da/publications/b1ba31e5-0840-4941-91b2-2218550c4b91

Abstract OT1-01-05: AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

Autor: Luc Dirix, Manon T. Huizing, Hans Wildiers, Eveline De Cuypere, Sarah Khan, Frederik Marmé, Carolina P. Schröder, Anne C Armstrong, Andreas Schneeweiss, Jans Huober, Frédéric Triebel

Publikováno v: Cancer Research. 80:OT1-01

Background: Eftilagimod alpha (efti, previously IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II and mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Efti may lead to the activation of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::267890b8e626703d9bc32af877ae6928
https://doi.org/10.1158/1538-7445.sabcs19-ot1-01-05

Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II

Autor: Agnes Jager, Luc Dirix, Manon T. Huizing, François Duhoux, Chrystelle Brignone, Doris Breiner, Guy Jerusalem, Frédéric Triebel, Christian Mueller, Eveline De Cuypere, Peter Vuylsteke

Publikováno v: Journal of Clinical Oncology. 36:1050-1050

1050Background: Eftilagimod alpha (efti, previously IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II and mediates antigen-presenting cell (APC) activation followed by CD8 ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3321b8d25606044f5382053396dd420
https://doi.org/10.1200/jco.2018.36.15_suppl.1050